sutent
pfizer limited - sunitinibi - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiset aineet - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
sunitinib ratiopharm 12.5 mg kapseli, kova
ratiopharm gmbh - sunitinib - kapseli, kova - 12.5 mg - sunitinibi
sunitinib ratiopharm 25 mg kapseli, kova
ratiopharm gmbh - sunitinib - kapseli, kova - 25 mg - sunitinibi
sunitinib ratiopharm 37.5 mg kapseli, kova
ratiopharm gmbh - sunitinib - kapseli, kova - 37.5 mg - sunitinibi
sunitinib ratiopharm 50 mg kapseli, kova
ratiopharm gmbh - sunitinib - kapseli, kova - 50 mg - sunitinibi
sunitinib sandoz 12.5 mg kapseli, kova
sandoz a/s - sunitinib - kapseli, kova - 12.5 mg - sunitinibi
sunitinib sandoz 25 mg kapseli, kova
sandoz a/s - sunitinib - kapseli, kova - 25 mg - sunitinibi
sunitinib sandoz 37.5 mg kapseli, kova
sandoz a/s - sunitinib - kapseli, kova - 37.5 mg - sunitinibi
sunitinib sandoz 50 mg kapseli, kova
sandoz a/s - sunitinib - kapseli, kova - 50 mg - sunitinibi
sunitinib stada 12.5 mg kapseli, kova
stada arzneimittel ag - sunitinib - kapseli, kova - 12.5 mg - sunitinibi